Literature DB >> 7631518

Bases for the early immune response after rechallenge or component vaccination in an animal model of acute Mycoplasma pneumoniae pneumonitis.

N Cimolai1, D G Mah, G P Taylor, B J Morrison.   

Abstract

The pathology of Mycoplasma pneumoniae pulmonary infection for a hamster model was examined after whole bacterium rechallenge or component vaccination. Animals which, after an initial infection, were rechallenged with either live or heat-killed M. pneumoniae inocula developed severe early recall lesions in the first 3 days. In contrast, animals infected once develop maximum histopathology at approximately 10-14 days. A severe perivascular inflammatory cellular infiltrate developed in the rechallenged groups, and pulmonary pathology could also be elicited by rechallenge with bacterial growth medium components. Component vaccination with protein P1 did not reduce disease in comparison to once-infected controls, and vaccination promoted an early immune recall response as well. We conclude that an early immune response needs to be sought in all future experiments of challenge/rechallenge or vaccination. Vaccine studies will require an understanding of both protective and harmful immunogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631518     DOI: 10.1016/0264-410x(95)93318-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Vaccination of BALB/c mice with an avirulent Mycoplasma pneumoniae P30 mutant results in disease exacerbation upon challenge with a virulent strain.

Authors:  S M Szczepanek; S Majumder; E S Sheppard; X Liao; D Rood; E R Tulman; S Wyand; D C Krause; L K Silbart; S J Geary
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

Review 3.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  Susceptibility Analysis in Several Mouse Strains Reveals Robust T-Cell Responses After Mycoplasma pneumoniae Infection in DBA/2 Mice.

Authors:  Shigeyuki Tamiya; Eisuke Yoshikawa; Koichiro Suzuki; Yasuo Yoshioka
Journal:  Front Cell Infect Microbiol       Date:  2021-01-13       Impact factor: 5.293

Review 5.  Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development.

Authors:  Zhulin Jiang; Shuihong Li; Cuiming Zhu; Runjie Zhou; Polly H M Leung
Journal:  Pathogens       Date:  2021-01-25

6.  Defining protective epitopes for COVID-19 vaccination models.

Authors:  Nevio Cimolai
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

Review 7.  Non-primate animal models for pertussis: back to the drawing board?

Authors:  Nevio Cimolai
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-01       Impact factor: 4.813

Review 8.  Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2020-11-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.